VRAP-Heart - Virtual Reality Assisted Patient Empowerment for Interventions in Structural Heart Disease
Launched by HEINRICH-HEINE UNIVERSITY, DUESSELDORF · Sep 22, 2022
Trial Information
Current as of June 10, 2025
Unknown status
Keywords
ClinConnect Summary
The VRAP-Heart clinical trial is studying how using virtual reality (VR) can help patients better understand their treatment for severe aortic valve stenosis, a condition where the heart's aortic valve doesn't open properly. This trial is for patients who are scheduled to undergo a specific procedure called a transfemoral transcatheter aortic valve implantation (TAVI), which replaces the damaged valve without major surgery. The researchers want to see if VR can improve patient education and comfort, potentially leading to fewer complications and shorter hospital stays.
To be eligible for the trial, participants should be at least 18 years old, have been diagnosed with severe aortic valve stenosis, and have a doctor’s recommendation for the TAVI procedure. Participants will learn about their treatment through virtual reality, which may make the experience more engaging and easier to understand. It’s important to know that some individuals, such as those who might have severe hearing or vision issues, advanced dementia, or are currently pregnant, cannot participate. The trial is currently recruiting patients, and everyone involved will need to provide informed consent, meaning they agree to participate after understanding what the study involves.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • High-grade aortic valve stenosis
- • Indication for elective transfemoral transcatheter aortic valve implantation under analgesia (TAVI)
- • Existing heart center decision
- • Age ≥ 18 years
- • Signed informed consent form
- Exclusion Criteria:
- • Surgery planned under general anesthesia
- • Language barrier
- • Severe hearing or vision impairment
- • Advanced dementia syndrome
- • Known seizure disorder (epilepsy)
- • Positive pregnancy test on inclusion and/or pregnancy is present
- • Court ordered placement in an institution
- • Any psychosocial condition that makes compliance with the protocol unlikely
About Heinrich Heine University, Duesseldorf
Heinrich-Heine University Düsseldorf is a leading academic institution dedicated to advancing medical research and education. Renowned for its innovative approach to healthcare and interdisciplinary collaboration, the university plays a pivotal role in clinical trials aimed at improving patient outcomes and translating scientific discoveries into clinical practice. With a robust infrastructure and a commitment to ethical standards, Heinrich-Heine University fosters an environment that supports cutting-edge research initiatives, contributing significantly to the advancement of medical knowledge and therapeutic interventions.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Düsseldorf, Nrw, Germany
Patients applied
Trial Officials
Christian Jung, Prof MD PhD
Principal Investigator
Heinrich-Heine University, Duesseldorf
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials